评估支持乳腺癌患者的数字工具:一项随机对照试验方案(ADAPT)
该随机对照试验方案旨在评估移动应用OWise Breast Cancer对早期乳腺癌患者自我管理(以PAM-13问卷测量的患者激活)的影响,并比较健康相关生活质量、心理困扰、健康状况及NHS卫生资源利用的变化。研究将1:1随机分配至标准护理或标准护理加OWise,在诊断前及诊断后3、6、12个月收集问卷,并与Discover综合护理记录链接。研究还计划测量对照组污染并调整样本量以减少效应估计稀释。
要点
- 评估OWise应用对早期乳腺癌患者3个月时患者激活(PAM-13)的影响
- 比较标准护理与标准护理加OWise在生活质量、心理困扰、健康状况及NHS资源利用的差异
- 通过测量和调整对照组污染来减少效应估计稀释,并进行符合方案集分析作为敏感性分析
核心结论
- 该研究旨在为OWise改善早期乳腺癌女性患者激活的有效性提供证据,结果将显示工具在患者层面和NHS卫生系统层面的影响。
研究设计与样本
- 随机对照试验,纳入早期乳腺癌患者,1:1随机分配至标准护理或标准护理加OWise。
- 参与者在开始抗癌治疗前及诊断后3、6、12个月完成问卷。
- 临床和患者报告结局数据将与Discover综合护理记录链接。
- 将测量对照组污染并调整样本量以减轻效应估计稀释,进行符合方案集分析作为敏感性分析。
- 试验于2019年3月7日在ClinicalTrials.gov注册(NCT03866655)。
关键数值与推荐
- 主要结局为诊断后3个月时通过PAM-13问卷测量的患者激活。
- 次要结局包括健康相关生活质量、心理困扰、健康状况和NHS卫生资源利用的变化。
临床怎么用
- 若研究显示OWise有效,结果可能影响该应用在NHS乳腺癌患者中的推广,并扩展至其他肿瘤类型。
局限性
- 评估公开可用的mHealth工具对试验者构成挑战,存在对照组污染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are a growing number of mHealth tools for breast cancer patients but a lack of scientific evidence for their effects. Recent studies have shown a mix of positive and negative impacts on users. Here we will assess the impact of OWise Breast Cancer, a mobile application for self-monitoring symptoms and managing care, on the process of self-management. METHODS: This randomized controlled trial with early stage breast cancer patients will assess the effect of OWise use on patient activation at 3 months from diagnosis measured by the PAM-13 questionnaire. We will also assess differences in changes in health-related quality of life, psychological distress, health status, and National Health Service (NHS) health resource utilization over the first year from diagnosis. Participants will be randomly allocated (1:1) to standard care or standard care plus OWise. Participants will complete questionnaires before starting anti-cancer treatment and at 3, 6, and 12 months from diagnosis. Clinical and patient-reported outcome data will be linked to health resource utilization data from Discover, an integrated care record of primary, secondary, and social care in North West London. We will measure contamination in the control group and adjust the sample size to mitigate the dilution of effect estimates. A per-protocol analysis will be conducted as a sensitivity analysis to assess robustness of the primary results. DISCUSSION: This study aims to generate evidence for the effectiveness of OWise at improving patient activation for women with early-stage breast cancer. The results will show the impact of using the tool at the patient level and the NHS health system level. The outcomes of the study will have implications for the application of OWise across the NHS for breast cancer patients and expansion into other tumor types. Assessing publicly available mHealth tools poses a challenge to trialists due to the risk of contamination. Here we apply various methods to measure, mitigate, and assess the effects of contamination. TRIAL REGISTRATION: The study was registered at clincaltrials.gov (NCT03866655) on 7 March 2019.
引用
- Lidington E, McGrath SE, Noble J, et al. Evaluating a digital tool for supporting breast cancer patients: a randomized controlled trial protocol (ADAPT). Trials. 2020. PMID: 31941539. doi:10.1186/s13063-019-3971-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。